Longboard Pharmaceuticals’ stock $LBPH skyrocketed by more than 200% Tuesday after the company released topline data from its study for an oral drug to treat seizures associated with developmental and epileptic encephalopathies.
Longboard published initial results from Phase Ib/IIa of the company’s PACIFIC study, which is evaluating bexicaserin, a 5-HT2C receptor superagonist. The study looked at 52 people aged 12 to 65 with DEE in the US and Australia and demonstrated a 53% seizure reduction compared to about 21% in the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.